Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) — Strategic Asset Allocation Index
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) has a Strategic Asset Allocation Index of 611.5% as of September 2022. Strategic assets (PP&E of CN¥189.69 Million plus long-term investments of CN¥-) total CN¥189.69 Million, measured against net assets of CN¥31.02 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See debt-free asset ratio of Hangzhou TianMuShan Pharmaceutical Enter to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd Strategic Asset Allocation Index (2000–2021)
This chart shows how Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's Strategic Asset Allocation Index has evolved across 22 annual periods from 2000 to 2021. As of September 2022, the index stands at 611.5%, representing strategic assets of CN¥189.69 Million against net assets of CN¥31.02 Million CNY. For live market cap and overall valuation, see Hangzhou TianMuShan Pharmaceutical Enter (600671) market capitalisation.
Annual Strategic Asset Allocation Index for Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (2000–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd from 2000 to 2021, covering 22 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See 600671 book value for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 309.5% | CN¥199.82 Million | CN¥199.82 Million | CN¥- | CN¥64.56 Million | ▲ +95.1 pp |
| 2020 | 214.4% | CN¥200.12 Million | CN¥200.12 Million | CN¥- | CN¥93.33 Million | ▲ +78.7 pp |
| 2019 | 135.7% | CN¥180.91 Million | CN¥180.91 Million | CN¥- | CN¥133.33 Million | ▼ -73.0 pp |
| 2018 | 208.7% | CN¥170.37 Million | CN¥168.62 Million | CN¥1.75 Million | CN¥81.62 Million | ▲ +55.4 pp |
| 2017 | 153.4% | CN¥147.64 Million | CN¥145.89 Million | CN¥1.75 Million | CN¥96.27 Million | ▼ -52.2 pp |
| 2016 | 205.6% | CN¥136.04 Million | CN¥126.69 Million | CN¥9.35 Million | CN¥66.18 Million | ▼ -24.6 pp |
| 2015 | 230.1% | CN¥144.42 Million | CN¥135.04 Million | CN¥9.37 Million | CN¥62.76 Million | ▲ +93.3 pp |
| 2014 | 136.8% | CN¥116.62 Million | CN¥116.62 Million | CN¥- | CN¥85.25 Million | ▲ +29.1 pp |
| 2013 | 107.7% | CN¥102.64 Million | CN¥102.64 Million | CN¥- | CN¥95.26 Million | ▲ +4.4 pp |
| 2012 | 103.4% | CN¥95.88 Million | CN¥95.88 Million | CN¥- | CN¥92.76 Million | ▲ +50.6 pp |
| 2011 | 52.8% | CN¥96.51 Million | CN¥96.51 Million | CN¥- | CN¥182.84 Million | ▼ -9.4 pp |
| 2010 | 62.2% | CN¥95.82 Million | CN¥95.82 Million | CN¥- | CN¥154.14 Million | ▲ +9.8 pp |
| 2009 | 52.4% | CN¥98.30 Million | CN¥98.30 Million | CN¥- | CN¥187.74 Million | ▲ +13.9 pp |
| 2008 | 38.4% | CN¥92.32 Million | CN¥92.32 Million | CN¥- | CN¥240.30 Million | ▲ +6.8 pp |
| 2007 | 31.6% | CN¥89.54 Million | CN¥89.54 Million | CN¥- | CN¥282.93 Million | ▼ -16.3 pp |
| 2006 | 47.9% | CN¥113.36 Million | CN¥113.36 Million | CN¥- | CN¥236.44 Million | ▲ +0.5 pp |
| 2005 | 47.5% | CN¥113.60 Million | CN¥113.60 Million | CN¥- | CN¥239.39 Million | ▲ +5.6 pp |
| 2004 | 41.9% | CN¥105.66 Million | CN¥105.66 Million | CN¥- | CN¥252.36 Million | ▼ -2.1 pp |
| 2003 | 44.0% | CN¥106.72 Million | CN¥106.72 Million | CN¥- | CN¥242.64 Million | ▼ -4.9 pp |
| 2002 | 48.9% | CN¥123.70 Million | CN¥123.70 Million | CN¥- | CN¥253.20 Million | ▲ +3.1 pp |
| 2001 | 45.7% | CN¥115.10 Million | CN¥115.10 Million | CN¥- | CN¥251.63 Million | ▼ -0.1 pp |
| 2000 | 45.8% | CN¥115.11 Million | CN¥115.11 Million | CN¥- | CN¥251.29 Million | — |